

Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-May-2018
Document Type: USP Monographs
DocId: GUID-37AD54E9-4D29-4FD2-99BD-B58C34333F98_3_en-US
DOI: https://doi.org/10.31003/USPNF_M37390_03_01
DOI Ref: z0gml

© 2025 USPC
Do not distribute

Histamine Phosphate Injection

» Histamine Phosphate Injection is a sterile solution of Histamine Phosphate in Water for Injection. It contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of $C_5H_9N_3 \cdot 2H_3PO_4$.

Packaging and storage—Preserve in single-dose or in multiple-dose containers, preferably of Type I glass, protected from light.

USP REFERENCE STANDARDS (11)—

[USP Histamine Dihydrochloride RS](#)

Identification—

A: Evaporate a volume of Injection, equivalent to about 2 mg of histamine phosphate, on a steam bath to dryness, dissolve the residue in 0.5 mL of water, and add 0.5 mL of 1 N sodium hydroxide. Add 2 drops of sodium nitrite solution (1 in 10), and add 1 mL of a solution prepared by mixing 50 mg of sulfanilic acid with 10 mL of water containing 2 drops of hydrochloric acid: an orange-red color is produced.

B: To 1 mL of Injection, equivalent to not less than 1 mg of histamine phosphate (concentrate a larger volume by evaporation, if necessary), add ammonium molybdate TS dropwise: a yellow precipitate, which is soluble in ammonia TS, is formed.

BACTERIAL ENDOTOXINS TEST (85)—It contains not more than 125.0 USP Endotoxin Units per mg of histamine phosphate.

pH (791): between 3.0 and 6.0.

Other requirements—It meets the requirements under [Injections and Implanted Drug Products \(1\)](#).

Assay—

Standard preparation—Dissolve an accurately weighed quantity of [USP Histamine Dihydrochloride RS](#) in water, and quantitatively dilute with water to obtain a solution having a known concentration of 20 μ g per mL, equivalent to 33.4 μ g of histamine phosphate.

Assay preparation—Dilute an accurately measured volume of Injection, equivalent to about 1.65 mg of histamine phosphate, with water in a 50-mL volumetric flask to volume, and mix.

If phenol is present, prepare the **Assay preparation** as follows. Dilute an accurately measured volume of Injection, equivalent to about 1.65 mg of histamine phosphate, with water to about 25 mL. Heat the solution on a steam bath until the odor of phenol is no longer perceptible, adding water as required to maintain a volume of about 15 mL. Transfer to a 50-mL volumetric flask, cool, dilute with water to volume, and mix.

Procedure—Pipet 5 mL each of the **Standard preparation** and the **Assay preparation** into separate, 10-mL volumetric flasks, to each add 1 mL of sodium borate solution (1 in 100), followed by 1 mL of a freshly prepared solution of 50 mg of β -naphthoquinone-4-sodium sulfonate in 10 mL of water. Place the flasks in boiling water for 10 minutes, then immerse them for 5 minutes in water maintained between 5° and 10°. To each flask, add 1 mL of acid-formaldehyde (made by adding 0.5 mL of formaldehyde TS to a mixture of 45 mL of 1 N hydrochloric acid and 10 mL of glacial acetic acid and diluting with water to 80 mL), mix, add 1 mL of 0.1 N sodium thiosulfate, then dilute with water to volume, and mix. Concomitantly and immediately determine the absorbances of both solutions at the wavelength of maximum absorbance at about 460 nm, with a suitable spectrophotometer, against a reagent blank. Calculate the quantity, in mg, of $C_5H_9N_3 \cdot 2H_3PO_4$ in each mL of the Injection taken by the formula:

$$C(0.0835/V)(A_u/A_s)$$

in which C is the concentration, in μ g per mL, of [USP Histamine Dihydrochloride RS](#) in the **Standard preparation**; V is the volume, in mL, of Injection taken; and A_u and A_s are the absorbances of the solutions from the **Assay preparation** and the **Standard preparation**, respectively.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
HISTAMINE PHOSPHATE INJECTION	Documentary Standards Support	SM32020 Small Molecules 3

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. Information currently unavailable

Current DocID: GUID-37AD54E9-4D29-4FD2-99BD-B58C34333F98_3_en-US

Previous DocID: GUID-37AD54E9-4D29-4FD2-99BD-B58C34333F98_1_en-US

DOI: https://doi.org/10.31003/USPNF_M37390_03_01

DOI ref: z0gml

OFFICIAL